Antibiotic Adjuvants: An Approach to Overcoming Multi-Drug Resistance and Biofilm Infections
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiofilm Strategies".
Deadline for manuscript submissions: closed (15 August 2024) | Viewed by 7434
Special Issue Editors
Interests: azamacrocyles; antimicrobials; antitumorals; metallodrugs
Special Issues, Collections and Topics in MDPI journals
Interests: bioactive compounds; antitumor compounds; antimicrobial compounds; immunomodulation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The incidence of infectious diseases caused by multi-drug-resistant pathogens has been increasing over the last few decades. These microorganisms are difficult to eradicate and are associated with worst outcomes than those caused by the respective susceptible strains. In addition, biofilm-associated microorganisms have shown a much higher resistance to antibiotics than planktonic microorganisms. While the emergence of multi-drug resistance has been associated with the misuse and abuse of antimicrobials, the number of available effective drugs is decreasing and novel compounds being introduced into the market are scarce. Therefore, current available antibiotic treatments often have limited or no efficacy against healthcare-associated infections (HCAIs), and novel therapeutic strategies need to be considered. This Special Issue aims to gather papers describing novel approaches to overcome infections caused by multi-drug-resistant microorganisms and/or those producing biofilms. In this context, papers on the description of antibiotic adjuvants are particularly welcome.
Dr. Luis G. Alves
Dr. Fatima Cerqueira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug resistance
- biofilm
- drug design
- antibiotic adjuvants
- antimicrobial synergy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.